id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0128-0009,FDA,FDA-2008-D-0128,"How Should Liver Injury and Dysfunction Caused by Drugs Be
Measured, Evaluated, and Acted Upon in Clinical Trials?",Notice,Public Meetings,2016-01-15T05:00:00Z,2016,1,2016-01-15T05:00:00Z,,2016-01-15T15:37:50Z,2016-00690,0,0,0900006481e11cc8
FDA-2008-D-0128-0008,FDA,FDA-2008-D-0128,Serious Drug-Induced Liver Injury The Importance of Getting It Right How To Measure and Interpret Drug-Induced Liver Injury Information and Make Correct Diagnoses Public Conference Request for Comments,Notice,Notice of Conference,2014-12-19T05:00:00Z,2014,12,2014-12-19T05:00:00Z,,2016-01-06T18:58:08Z,2014-29720,0,0,0900006481985fad
FDA-2008-D-0128-0007,FDA,FDA-2008-D-0128,"Serious Drug-Induced Liver Injury: Who Gets It? Who Doesn’t? Why?;
Public Conference; Request for Comments",Notice,Notice of Conference,2014-02-10T05:00:00Z,2014,2,2014-02-10T05:00:00Z,,2016-01-06T18:57:06Z,2014-02755,0,0,09000064815564b9
FDA-2008-D-0128-0006,FDA,FDA-2008-D-0128,"Detecting and Evaluating Drug-Induced Liver Injury; What's Normal, What's Not, and What Should We Do About It",Notice,Notice of Conference,2013-01-28T05:00:00Z,2013,1,2013-01-28T05:00:00Z,,2024-11-12T05:13:20Z,2013-01640,1,0,09000064811dab16
FDA-2008-D-0128-0004,FDA,FDA-2008-D-0128,Guidance for Industry on Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Availability,Notice,Notice of Availability,2009-07-30T04:00:00Z,2009,7,2009-07-30T04:00:00Z,,2016-01-06T18:52:41Z,E9-18135,0,0,09000064809fe4c8
FDA-2008-D-0128-0005,FDA,FDA-2008-D-0128,Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Guidance for Industry,Other,Guidance,2009-07-29T04:00:00Z,2009,7,2009-07-29T04:00:00Z,,2024-11-12T04:35:42Z,,1,0,09000064809fe510
FDA-2008-D-0128-0001,FDA,FDA-2008-D-0128,Draft Guidance for Industry on Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Reopening of Comment Period; Public Conference,Notice,NEC-Notice of Extension,2008-03-06T05:00:00Z,2008,3,2008-03-06T05:00:00Z,2008-07-01T03:59:59Z,2008-07-02T01:22:26Z,E8-04361,0,0,09000064803e9744
FDA-2008-D-0128-0002,FDA,FDA-2008-D-0128,Draft Guidance for Industry - Drug-Induced Liver Injury: Premarketing Clinical Evaluation,Other,Guidance,2008-03-06T05:00:00Z,2008,3,2008-03-06T23:35:27Z,2008-07-01T03:59:59Z,2016-01-06T18:51:41Z,,0,0,09000064803ea4f0